Sagent (SGNT) Launches Flumazenil Injection

Sagent Pharmaceuticals, Inc. (Nasdaq: SGNT) announced the launch of Flumazenil Injection, USP, a benzodiazepine antagonist, in two latex-free vial presentations. According to IMS for the 12 months ending September 2012, the US market for Flumazenil Injection, USP approximated $5.6 million. As with all products in Sagent's portfolio, Flumazenil features the Company's PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Silexion reports new preclinical immune data for SIL204 in KRAS cancers
• Sagtec Global CEO and COO buy shares in private transactions
• Marvell unveils new AI memory infrastructure products at FMS 2026